ClinicalTrials.gg
CompletedNCT03569787Updated Jun 26, 2018

Hyperprolactinaemia Management in Reproductive Services at University Hospital of Coventry and Warwickshire

An observational study in Hyperprolactinemia, Subfertility and Subclinical hypothyroïdism, sponsored by University Hospitals Coventry and Warwickshire NHS Trust. Completed at 1 site in United Kingdom. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-26.

Sponsored by University Hospitals Coventry and Warwickshire NHS Trust · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
107
Sex
Female
01

Study summary

Hyperprolactinaemia and thyroid disorders can significantly reduce fertility by causing ovulatory dysfunction. There is no evidence to suggest treatment of hyperprolactinaemia in the presence of regular ovulatory menstruation will improve fertility. However, anecdotal observation of practice at UHCW NHS Trust suggested that dopamine agonists are often prescribed irrespective of whether symptoms of hyperprolactinaemia are present.

The aim of the study was to establish the prevalence of hyperprolactinaemia and incidence of subclinical hypothyroidism in patients undergoing subfertility investigations at UHCW NHS Trust. Also, to examine management of patients with hyperprolactinaemia and a normal pituitary MRI scan, and explore the trends in treatment; and finally, to explore how this could improve reproductive services.

107 patients were identified as having a high prolactin reading between January 2014 and January 2017. Hospital records were examined for patient demographics, relevant blood and scan results, medical history, any treatment, and treatment outcomes.

The prevalence of hyperprolactinaemia was 23%. 20.6% of patients had suboptimal thyroid function and were started on levothyroxine. Prolactin levels, and presence of relevant symptoms, only had a partial bearing on whether dopamine agonists were used in those with normal pituitary MRI results (or where no scan was performed). The use of dopamine agonists appeared to correlate with assisted conception and a lower incidence of birth complications (inc. miscarriage, prematurity), though the significance of this was limited by the size of the dataset.

Dopamine agonists often appeared to be used in more complex patients, rather than exclusively those with a higher prolactin reading and/or the presence of related symptomatology. Patients frequently underwent a pituitary MRI scan in the absence of symptoms, contrary to evidence. The findings suggest that less patients should be scanned and less treated with dopamine agonists. A health economics evaluation study would be useful to elucidate the potential cost saving this could represent. It may be better to prioritise optimisation of thyroid function, particularly when noting the similarities in the prevalence of suboptimal thyroid function and that of hyperprolactinaemia.

02

Conditions studied

  • Hyperprolactinemia
  • Subfertility
  • Subclinical hypothyroïdism
03

In context

Hyperprolactinemia

39 studies on the registry are indexed under Hyperprolactinemia; 4 are open to participants now.

This study's enrollment of 107 is close to the median of 114 across 16 observational studies indexed under Hyperprolactinemia.

Browse Hyperprolactinemia studies →

Lead sponsor

University Hospitals Coventry and Warwickshire NHS Trust is the lead sponsor of 57 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All patients seen in subfertility services at UHCW between January 2014 to October 2017

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergoing care through subfertility services at UHCW
  • Referred and seen in subfertility services between January 2014 to October 2017
  • Identified as having had at least one episode of hyperprolactinaemia within the study period (Jan 2014 to January 2017)

Exclusion criteria

Exclusion Criteria:

  • Referred outside of study period
  • Hyperprolactinaemia reading outside of study period
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
107 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients with hyperprolactinaemia

    Patients undergoing subfertility studies with at least one high prolactin reading (\>500mU/L).

    Diagnostic Test: MRI Pituitary

Interventions

  • Diagnostic testMRI Pituitary

    Identification of whether of not patients had had an MRI pituitary following hyperprolactinaemia reading

06

What researchers measure

Primary outcomes

  1. Number of people referred to subfertility services identified as having at least one high serum prolactin result (>500mU/L) as identified by UHCW CRRS (University Hospital of Coventry and Warwickshire Clinical Records Reporting System) records

    Not to date of study start to allow period to follow up on conception and birth data

    Time frame: January 2014 - January 2017

  2. Number of patients who received a course of dopamine agonist (of any length, at any point during access to subfertility services) as identified by UHCW CRRS (University Hospital of Coventry and Warwickshire Clinical Records Reporting System) records

    This typically included bromocriptine or cabergoline. Whether or not they were concurrently treated with Levothyroxine was also recorded (either for new subclinical hypothyroidism or coexisting previously diagnosed hypothyroidism).

    Time frame: January 2014 - January 2017

  3. Number of patients who received a pituitary MRI scan, and the reported result, as identified by UHCW CRRS records

    Time frame: January 2014 - October 2017

Secondary outcomes

  1. Demographics of the mother, including: age at referral, BMI at referral, ethnicity, whether primary or secondary subfertility, previous parities, smoking status, any recorded alcohol consumption as identified by UHCW CRRS records

    Time frame: January 2014 - October 2017

  2. Demographics of father, including: smoking status, any alcohol consumption, semen analysis result, whether the father is receiving treatment for improving semen quality as identified by UHCW CRRS records

    Time frame: January 2014 - October 2017

  3. Relevant blood results for mother (outlined in desciption), as close as possible to referral date to subfertility services as identified by UHCW CRRS records

    Including: anti-mullerian hormone (mU/L); oestrodiol; FSH (IU/L); LH (IU/L); testosterone (nmol/L); SHBG; androstenedione; TSH (mU/L); free T4 (pmol/L); TPO antibodies; TSH receptor antibodies; macroprolactin (where negative is more than 50% recovery following PEG test)

    Time frame: January 2014 - October 2017

  4. Number of patients who experienced symptoms of hyperprolactinaemia, namely any record of: amenorrhoea, oligomenorrhoea, galactorrhoea (inc. whether unilateral or bilateral) and any other relevant symptoms recorded as identified by UHCW CRRS records

    Time frame: January 2014 - October 2017

  5. Number of patients identified as having PCOS, including what elements of the Rotterdam Criteria led to diagnosis as identified by UHCW CRRS records

    Time frame: January 2014 - October 2017

  6. Number of patients with pre-exisitng thyroid disorder, any past medical history, and/or any concomitant medications as identified by UHCW CRRS records

    Time frame: January 2014 - October 2017

  7. Number of patients that managed to conceive, if this was spontaneous (and if not, by what method of assistance), and the outcome of the pregnancy as identified by UHCW CRRS records

    Outcome of pregnancy categorised by: birth at term, premature birth, miscarriage, stillbirth or ectopic

    Time frame: January 2014 - October 2017

07

Study locations

1 site
  • Megan Crowe
    Coventry, CV22DX, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03569787
Lead sponsor
University Hospitals Coventry and Warwickshire NHS Trust
Responsible party
Sponsor
First posted
Jun 26, 2018
Start date
Sep 25, 2017
Primary completion
Dec 1, 2017
Completion
Dec 1, 2017
Last update
Jun 26, 2018

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion